Companies
S&P 500Health Care· USA
REGN
Status-Quo-PlayerRegeneron Pharmaceuticals
ODISUM
$746.46
-0.33%
Open $747.74·Prev $748.96
as of 13 Apr
STATUS-QUO-PLAYER
Power Core
Regeneron's moat is its proprietary VelociSuite technology platform, which enables the repeated, industrialized discovery of fully human antibodies at a speed and cost structure that competitors cannot match from conventional discovery methods.
Published1 Apr 2026
UniverseS&P 500
SectorHealth Care
↑
Direction of Movement
Dupixent Growth and Pipeline Maturation Drive Upward Trajectory
ROC 200
+45.8%
